Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center,Middle East, Phase-II Study, Non-comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients With Advanced Renal Cell Carcinoma to Evaluate The Efficacy and Tolerability of the Drug

NCT00848640 is registered in ClinicalTrials.gov with Egyptian Foundation For Cancer Research as lead sponsor.

NCT NCT00848640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00848640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center,Middle East, Phase-II Study, Non-comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients With Advanced Renal Cell Carcinoma to Evaluate The Efficacy and Tolerability of the Drug
Lead sponsor
Egyptian Foundation For Cancer Research
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2008
Completion date
March 31, 2010
Enrollment
75 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma